Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases, Will Pay Ionis $1B In Cash Which Will Include $625M TO Purchase 11.5M Shares Of Ionis Stock At $54.34/Share